A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer
Dustin A Deming, Ludmila L Cavalcante, Sam J Lubner, Daniel L Mulkerin, Noelle K LoConte, Jens C Eickhoff, Jill M Kolesar, Suzanne Fioravanti, Tim F Greten, Kathryn Compton, Austin G Doyle, George Wilding, Austin Duffy, Glenn Liu, Dustin A Deming, Ludmila L Cavalcante, Sam J Lubner, Daniel L Mulkerin, Noelle K LoConte, Jens C Eickhoff, Jill M Kolesar, Suzanne Fioravanti, Tim F Greten, Kathryn Compton, Austin G Doyle, George Wilding, Austin Duffy, Glenn Liu
Abstract
Background: KRAS mutations are clinically important predictors of resistance to EGFR-directed therapies in colorectal cancer (CRC). Oncogenic activation of the RAS/RAF/MEK/ERK signaling cascade mediates proliferation independent of growth factor signaling. We hypothesized that targeting MEK with selumetinib could overcome resistance to cetuximab in KRAS mutant CRC.
Methods: A phase I study (NCT01287130) was undertaken to determine the tolerability, and pharmacokinetic profiles of the combination of selumetinib and cetuximab, with an expanded cohort in KRAS-mutant CRC.
Results: 15 patients were treated in the dose escalation cohort and 18 patients were treated in the expansion cohort. Two dose-limiting toxicities were observed. One grade 3 acneiform rash and one grade 4 hypomagnesemia occurred. The most common grade 1 and 2 adverse events included rash, nausea/vomiting, diarrhea, and fatigue. The maximum tolerated dose was established at selumetinib 75 mg p.o. BID and cetuximab 250 mg/m(2) weekly following a 400 mg/m(2) load. Best clinical response in the dose escalation group included 1 unconfirmed partial response in a patient with CRC and stable disease (SD) in 5 patients (1 squamous cell carcinoma of the tonsil, 1 non-small cell lung cancer, and 3 CRC), and in the KRAS-mutant CRC dose expansion cohort, of the 14 patients who were evaluable for response, 5 patients had SD and 9 patients had progressive disease.
Conclusions: The combination of selumetinib and cetuximab is safe and well tolerated. Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC. Further investigations might be warranted in other cancer subtypes.
Keywords: AZD6244; Cetuximab; Colon cancer; KRAS; Phase I; Selumetinib.
Conflict of interest statement
Conflict of interest
The authors declare that they have no conflict of interest.
Source: PubMed